Evidence map›Paper›PMID 37366949›Full record

ReviewBiosensors2023

Prospects of Microfluidic Technology in Nucleic Acid Detection Approaches.

Zilwa Mumtaz, Zubia Rashid, Ashaq Ali, Afsheen Arif, Fuad Ameen, Mona S AlTami, Muhammad Zubair Yousaf

Open access · goldAbstract readReview
In one paragraph

Review in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Development of RT-LAMP assay for variants of HCV in Pakistan.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Zilwa MumtazKAM School of Life Sciences, Forman Christian College University, Ferozpur Road, Lahore 54600, Pakistan.ORCID 0000-0002-7694-4265
Zubia RashidPure Health Laboratory, Mafraq Hospital, Abu Dhabi 1227788, United Arab Emirates.ORCID 0000-0002-8753-8385
Ashaq AliState Key Laboratory of Virology, Center for Biosafety MegaScience, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.ORCID 0000-0003-3224-2891
Afsheen ArifKarachi Institute of Biotechnology and Genetic Engineering (KIBGE), University of Karachi, Karachi 75270, Pakistan.
Fuad AmeenDepartment of Botany and Microbiology, College of Science, King Suad University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-5185-022X
Mona S AlTamiBiology Department, College of Science, Qassim University, Burydah 52571, Saudi Arabia.
Muhammad Zubair YousafKAM School of Life Sciences, Forman Christian College University, Ferozpur Road, Lahore 54600, Pakistan.ORCID 0000-0002-5087-7236
Forman Christian College · PKChinese Academy of Sciences · CNMafraq Hospital · AEQassim University · SAUniversity of Karachi · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional diagnostic techniques are based on the utilization of analyte sampling, sensing and signaling on separate platforms for detection purposes, which must be integrated to a single step procedure in point of care (POC) testing devices. Due to the expeditious nature of microfluidic platforms, the trend has been shifted toward the implementation of these systems for the detection of analytes in biochemical, clinical and food technology. Microfluidic systems molded with substances such as polymers or glass offer the specific and sensitive detection of infectious and noninfectious diseases by providing innumerable benefits, including less cost, good biological affinity, strong capillary action and simple process of fabrication. In the case of nanosensors for nucleic acid detection, some challenges need to be addressed, such as cellular lysis, isolation and amplification of nucleic acid before its detection. To avoid the utilization of laborious steps for executing these processes, advances have been deployed in this perspective for on-chip sample preparation, amplification and detection by the introduction of an emerging field of modular microfluidics that has multiple advantages over integrated microfluidics. This review emphasizes the significance of microfluidic technology for the nucleic acid detection of infectious and non-infectious diseases. The implementation of isothermal amplification in conjunction with the lateral flow assay greatly increases the binding efficiency of nanoparticles and biomolecules and improves the limit of detection and sensitivity. Most importantly, the deployment of paper-based material made of cellulose reduces the overall cost. Microfluidic technology in nucleic acid testing has been discussed by explicating its applications in different fields. Next-generation diagnostic methods can be improved by using CRISPR/Cas technology in microfluidic systems. This review concludes with the comparison and future prospects of various microfluidic systems, detection methods and plasma separation techniques used in microfluidic devices.

Indexed as

Communicable DiseasesMicrofluidic Analytical TechniquesNucleic AcidsHumansLab-On-A-Chip DevicesMicrofluidicsNucleic Acid Amplification TechniquesPoint-of-Care SystemsNucleic Acidsisothermal amplificationlab on chipmicrofluidicsmolecular diagnosticsnucleic acid detectionnucleic acid testingportable devices

Identifiers

PMID37366949
PMCPMC10296372
OpenAlexW4378528418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.